Amgen Inc (NAS:AMGN)
$ 309.47 1.02 (0.33%) Market Cap: 166.01 Bil Enterprise Value: 219.78 Bil PE Ratio: 44.21 PB Ratio: 33.06 GF Score: 88/100

Amgen Inc Conference Call on the BeiGene Collaboration Transcript

Oct 31, 2019 / 09:00PM GMT
Release Date Price: $213.25 (+1.12%)
Operator

My name is Laura, and I will be your conference facilitator today for Amgen's conference call. (Operator Instructions) I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Arvind Sood
Amgen Inc. - VP of IR

Okay. Thank you, Laura. Good afternoon, everybody, and thanks for joining us on short notice. Our announcement today of a strategic collaboration in oncology with BeiGene is an important step in expanding our presence in China and towards advancing the development of our oncology pipeline globally.

To discuss the strategic rationale of this acquisition, our CEO, Bob Bradway, will make some opening comments; followed by David Meline, our CFO, who will discuss the anticipated financial impact of this collaboration. After David's comments, we'll open it up for questions.

And in addition to Bob, Murdo Gordon, our Head of Global Commercial Operations; and Dave Reese, our Head of R&D, will also join us for the Q&A session. So my customary reminder that some of the statements we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot